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ABSTRACT 
The present study was undertaken to investigate the effects of the T-type calcium channel 
blocker, Mibefradil, on white adipocytes. Unexpected for a T-type channel blocker, Mibefradil 
was found to increase intracellular calcium levels, cause lipid droplet fusion, and result in cell 
death. Calcium imaging of white adipocytes showed an increase of calcium concentration by 
Mibefradil at concentrations ranging from10-50 µM. The elevation in calcium by Mibefradil was 
significantly reduced by pretreatment of cells with Thapsigargin, an endoplasmic reticulum (ER) 
specific Ca ATPase inhibitor. Additionally, lipid droplet fusion and cell death were also 
attenuated by Thapsigargin pretreatment in white adipocytes. We conclude that Mibefradil 
elevated intracellular calcium levels, induced lipid droplet fusion and cell death in white 
adipocytes via mobilizing intracellular calcium stores from the ER. These results describe novel 
effects of Mibefradil on white adipocytes and may provide new insight into how this drug might 
be repurposed in obesity research. 
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1 
1 METHODS 
Cell Culture 
All cells were maintained at 37 °C in a 5% CO2 incubator. White preadipocytes were kindly 
provided by Dr. Bingzhong Xue’s Lab. To differentiate mature adipocytes, we plated pre-
adipocytes with pre-adipocyte medium [Dulbecco’s Modified Eagle Medium (DMEM), 1:1 (v/v) 
containing 10% fetal calf serum, 15mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), and antibiotics]. Cells were grown into 90% confluence in growth medium and were 
then induced to differentiate with a differentiation medium [DMEM, 1:1 (v/v) containing 10% 
fetal bovine serum, 15mM HEPES, 33µM biotin, 17 µM pantothenate, 100nM insulin, 1 µM 
dexamethasone, 0.25 mM isobutyl methylxanthine (IBMX), 1 µM BRL49653, 100 U/ml 
penicillin, and 100 µg/ml streptomycin]. After two days in differentiation cocktail, cells were 
changed to and maintained in adipocyte medium [ DMEM/Ham’s F-10, 1:1 (v/v), 0.2% FBS, 15 
Mm HEPES, 33 µM biotin, 17 µM pantothenate, 100 U/ml penicillin, and 100 µg/ml 
streptomycin]. At day 6, all the cells were differentiated. 
Image acquisition and analysis  
Petri dishes containing white adipocytes were placed on a fixed stage that was centered below 
the objective of an upright microscope (BS51W1F, Olympus, Japan). The upright microscope 
was mounted on a manual translation stage (Siskiyou, San Francisco, CA). Phase contrast and 
fluorescent images of white adipocytes were captured before (-5 and 0 min) and at defined times 
after Mibefradil application. If pharmacological inhibitors were used in combination with 
Mibefradil application, the inhibitor was directly applied to the dish for the desired amount of 
time at the defined 5 min or 5 min 30 sec time marker. In the figures, changes in calcium 
concentration were expressed as a percent change comparing concentrations just before drug 
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addition and peak calcium levels after drug addition. In all experiments, the first calcium peak 
was used for analysis, because this was demonstrated to be the direct result of drug action. For 
cells in which the calcium concentration did not return to baseline calcium levels and that 
showed a continued increase in calcium level it was difficult to identify the first peak. In such 
cases, the time point at which all other cells showed their first peak after treatment was 
designated as the first peak value for a cell.   Statistical analysis was performed with the software 
ORIGIN DATA ANALYSIS AND GRAPHING software (OriginLab, Northampton, MA) 
Significance between conditions was determined by using either a Student’s t-test and ANOVA. 
All data were expressed as mean ± SEM.  
Ca2+ imaging  
Cells were loaded with 1mM fura-2 AM (Molecular Probes, Eugene, OR, USA) in DMSO and 
allowed to sit for 30 min to give the dye time to diffuse. Care was taken to load cells just enough 
to yield sufficient fluorescence and avoid overloading with Fura-2. Cells were washed 3x with 
extracellular medium (refer to pharmacological agents) then allowed to sit for 20 min for 
desertification. Acquisition and analysis of calcium images were conducted using Live 
Acquisition and Offline Analysis software (Till Photonics, FEI, Germany). Images were acquired 
using 340 nm and 380 nm excitation wavelengths with 100ms exposure time at 5% light 
intensity every 30 sec. The I cytosolic calcium concentration within an adipocyte was determined 
by placing a box into the cytosol area of each adipocyte and by calculating the ratio of emission 
signals at 340 and 380 nm after background subtraction. This ratio was used as a measure of 
underlying changes in intracellular calcium concentration. No actual calcium concentrations can 
be reported, because the fluorescence values were not calibrated on the imaging system. 
Adipocytes were excluded from analysis if their pretreatment ratios exceeded a ratio of 1, which 
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indicated a calcium concentration above normal resting values, as established in earlier 
experiments on the system. 
Pharmacological Agents 
Extracellular medium: 152 mM NaCl, 2.8 mM KCL, 10 mM HEPES, 2 mM Calcium Chloride, 
10 mM of glucose. Zero calcium extracellular medium: Same ingredients as extracellular 
medium excluding calcium chloride and addition of 5 mM EGTA. FCCP (Tocris) and Mibefradil 
(Tocris) were dissolved in DMSO. Final dilutions of DMSO in solutions were less than 1:1000. 
FCCP was dissolved in 72 µl of DMSO to make a stock solution of 5 mM. Mibefradil was 
dissolved in 172 µl of DMSO to make a stock solution 100 mM. 
  
 
 
 
  
4 
2 INTRODUCTION 
Obesity refers to a condition where excess fat accumulates on a person’s body posing various 
health risks to the individual. The word ‘obesity’ is sometimes used synonymously with the word 
‘adiposity,’ which refers to morbid or severe overweight. Obesity alters the endocrine and 
metabolic functions of white adipose tissue and increases the release of proinflammatory 
molecules, hormones, and fatty acids. In principle, the white adipose tissue functions as an 
energy reserve or active organ that employs different mechanisms to influence energy 
homeostasis (Bambace et al., 2013). Adiposity has been described as the part of body mass that 
comprises neutral lipids stored in the adipose tissue (Weisberg et al., (2003). It correlates closely 
with vital physiological parameters like leptin concentrations, insulin sensitivity, and blood 
pressure. Weisberg et al. (2003) reported the existence of positive correlations between adiposity 
and obesity-related disorders, especially glucose intolerance, dyslipidemia, and hypertension. 
However, the authors noted that visceral fat mass shows a closer correlation with obesity-related 
pathology than the overall adiposity. 
Adipose tissue plays a vital role in the lives of mammals because it serves as the primary source 
of free fatty acids (FFA) during postprandial fasting for heat production and energy use 
(Balistreri et al., 2010). Typically, mammals have two forms of adipose tissue: brown and white 
tissues (Gesta et al., 2007). The two types of adipose tissue have different functions, as well as 
different cellular localization and composition. White adipose tissue (WAT) is the major 
constituent of the adipose tissue and provides the largest proportion of body fat and FFA. In 
principle, WAT is distributed in various anatomic sites of the body with its primary depots being 
intra-abdominal areas, peri-renal and intestinal sites, and subcutaneous areas of the abdomen, 
thighs, and buttocks (Gesta et al., 2007). According to Wozniak et al. (2009), WAT appears to be 
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associated with two principal functions. First, it helps to control metabolism through insulin 
sensitivity, adipocyte differentiation, and energy homeostasis. Secondly, it influences 
inflammation through control mechanisms mediated by various anti-inflammatory molecules, as 
well as activated immune and anti-inflammatory pathways (Balistreri et al., 2010). Although 
each WAT subgroup has a specialized role, the excessive accumulation of WAT at any site of 
the body influences the occurrence of obesity, as well as obesity-related illnesses. The most 
common WAT excess occurs around the waist resulting in central obesity or ‘android obesity,’ 
which intensifies the risk of certain inflammatory pathologies (Balistreri et al., 2010). WAT 
excess may also occur in lower parts of the body causing the development of ‘gynoid obesity,’ 
which lacks metabolic complications (Gesta et al., 2007). 
Several hypotheses have been developed to shed light on the distribution of WAT and its 
relationship with inflammatory and metabolic complications. Among the different theories, two 
principal hypotheses have been given considerable attention. The first theory concentrates on 
central obesity’s anatomy and its potential to drain inflammatory mediators and FFA into portal 
circulation. In turn, the drained mediators and FFA act on the liver preferentially and affect 
metabolic reactions significantly (Gesta et al., 2007). The second hypothesis considers the role of 
different WAT cell properties in the development of inflammatory and metabolic diseases. Gesta 
et al. (2006) detected key differences in gene expression between different WAT deposits in both 
humans and rodents. Interestingly, other researchers have also observed a distinct mediator 
profile between peripheral and visceral WAT, which seems to elucidate the link that exists 
between metabolic complications and central obesity (Balistreri et al., 2010). The mediator 
profile offers additional evidence for the heterogeneity of the cells of WAT (Gesta et al., 2007). 
Also, WAT comprises fully-developed adipocytes and cell types such as macrophages, 
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endothelial cells, fibroblasts, and preadipocytes, which are categorized as the stroma vascular 
fractions (Cancello and Clement, 2006; Subramanian and Ferrante Jr., 2009). The macrophages, 
preadipocytes, and adipocytes have inflammatory and metabolic functions that allow the WAT to 
release mediators with varying biological effects (Fantuzzi, 2008; Lago et al., 2009). In 
particular, macrophages influence the circulating level of different inflammatory molecules and 
determine low-grade obesity-associated inflammation (Zeyda and Stulnig, 2007). 
In the mammalian body, energy is preserved in lipid droplets as triacylglycerols. Recently, 
researchers have made significant breakthroughs in promoting the understanding of lipid 
droplets’ biology (Walther and Farese Jr., 2012; Brasaemle and Wolins, 2012). In particular, 
microscopic observation has been identified as one of the most effective approaches to the 
visualization of the striking capacity of the white adipocyte lipid droplets (LDs) to store lipids 
(Konige et al., 2014). The majority of mature adipocytes contain a single lipid droplet within the 
size range of 25 to about 150 μm in diameter (Konige et al., 2014). The droplet occupies the 
largest cell volume and, thus, determines the size of the adipocyte. Also, adipose depots have 
been known to enlarge through the mechanisms of hyperplasia and hypertrophy, which require 
extensive and coordinated cellular and structural alterations to accommodate the growth and 
emergence of the LD. Different studies have demonstrated that LDs control the capacity and 
efficiency of adipocytes to carry out the esterification of fatty acids to form triglyceride and, 
hence, protect the triglyceride stores inside the cells (Puri et al., 2008). The proteins surrounding 
LDs comprise the ‘PAT’ proteins perilipin ADRP and TIP47 that target LDs and regulate the 
biogenesis 11and size of such organelles (Puri et al., 2008). Investigators have further described 
Cidec/FSP27 as a unique protein associated with lipid droplets, which negatively controls 
lipolysis and enhances triglyceride accumulation in adipocytes (Puri et al., 2008). Cidec/FSP27 
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has been classified as a CIDE-N type of domain-containing proteins in the protein family of 
CIDE, which includes three protein members found in mice: FSP27; Cideb; and Cide (Puri et al., 
2008). The CIDE family also includes four human proteins: CIDEC; CIDEB; and CIDEA. 
Notably, the proteins have a typical C-terminal containing CIDE-C domain and an N-terminal 
with a CIDE-N domain. In addition, the proteins have an important homology occurring between 
CIDE-N domains of the CIDE proteins and regulatory domains associated with apoptotic factors 
of DNA fragmentation, DFF45 (a DFF40 inhibitor) and DFF40 (nuclease activated by caspase) 
(Puri et al., 2008). Researchers also found that Cidec/FSP27 acts as an LD-related protein in the 
adipocytes of mice to control fat deposition. Moreover, Cidea has been known to show high 
expression in adipose tissues. In mice, the protein is primarily restricted to the brown adipose 
tissue but highly expressed in the human WAT. Puri et al. (2008) found substantial evidence 
supporting the view that Cidea localizes to LDs and controls the deposition of triglyceride in 
various cell types, including adipocytes. Remarkably, the researchers discovered that the 
expression of both Cidec/FSP27 and Cidea in the WAT of overweight human subjects shows a 
positive correlation with insulin sensitivity in the body, as well as the LD protein perilipin. Thus, 
obesity has been identified as one of the primary causes of diabetes. 
The magnitude and prevalence of obesity, especially in adolescents, is on the rise. Apart from 
environmental and genetic factors, the intake of calcium has been described as a key dietary 
component that shows an inverse relationship with obesity and body mass index (Burbano et al., 
2016). Recently, apoptosis modulation in the adipose tissue has emerged as a promising strategy 
against obesity because the elimination of adipocytes is expected to reduce body fat significantly. 
Studies have shown that Ca2+ signaling induces apoptosis in the adipocytes (Parikh and 
Yanovski, 2003). Therefore, intracellular calcium has a critical function in the metabolic 
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derangements linked to obesity. Shi et al. (2000) pointed out that increasing intracellular calcium 
by stimulating voltage-mediated or receptor calcium channels stimulates the activity and 
expression of the fatty acid synthase (FAS). FAS is crucial to the commencement of lipogenesis 
and inhibits both agonist-stimulated lipid breakdown and basal lipolysis in adipocytes. Such 
effects are often reversed through the antagonism of calcium channels (Shi et al., 2000). 
Accordingly, increasing intracellular calcium seems to exert a coordinated regulation over 
lipolysis and lipogenesis, which enhances the accumulation of triglyceride in adipocytes. As 
such, an increase in intracellular calcium simultaneously stimulates lipogenesis and suppresses 
lipolysis resulting in adipocyte hypertrophy and lipid filling. Past investigations have further 
implicated Ca2+ in the regulation of adipogenesis, which is thought to promote obesity in humans 
and rodents (Shi et al., 2000). For instance, increasing intracellular calcium, by inhibiting the 
CaATPase or stimulating the influx of calcium ions has been known to suppress the initial stages 
of adipocyte differentiation in murine (Shi et al., 2000). Thus, the effect of calcium signaling on 
body fat reduction provides a powerful rationale for developing mechanistic approaches to the 
study of calcium’s anti-obesity properties. Shi et al. (2000) reported that increasing intracellular 
calcium in the early phases of differentiation resulted in the suppression of adipocyte 
differentiation in humans, which matched previous observations about adipocyte differentiation 
in murine. On the other hand, increasing intracellular calcium during the late phases of 
differentiation enhanced human adipocyte differentiation (Shi et al., 2000). Therefore, 
considerable evidence suggests that promoting Ca2+ signaling has a biphasic regulatory function 
in the differentiation of human adipocytes. As a result, it inhibits the initial differentiation stages 
while enhancing the final stages of lipid filling and differentiation (Shi et al., 2000). The role of 
Ca2+ signaling in the differentiation of adipocytes not only elucidates the processes of energy 
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homeostasis and adipogenesis but also establishes a critical target for the future development of 
effective therapeutic interventions in obesity. Accordingly, Bagchi and Preuss (2012) 
recommended the use of dietary calcium as an anti-obesity strategy. The authors demonstrated 
that an increase in dietary calcium confers protection against obesity by reducing intracellular 
calcium levels, which in turn decreases lipid storage in the adipocytes.  
Our research on white adipocytes focused primarily on the presence of voltage gated calcium 
channels and their functional roles. Several voltage gated calcium channel blockers were utilized 
in our experiments. However, treatment of one such drug, Mibefradil, had the effect of 
increasing calcium levels in white adipocytes. Typically, Mibefradil is categorized as a calcium 
channel blocker because it affects calcium movements into the cells of blood vessels and the 
heart. Consequently, the agent relaxes the blood vessels while increasing oxygen and blood 
supply to the heart to minimize its workload. Additionally, Mibefradil functions as a tetraline 
substituted with benzimidazole. Thus, it selectively inhibits and binds the T-type forms of 
calcium channels. More specifically, Mibefradil acts as a tetralol-related calcium channel blocker 
that prevents the movement of calcium across the low-voltage T calcium channels and the high-
voltage L calcium channels in the vascular and cardiac smooth muscles (DrugBank, 2016). 
However, the drug is relatively more selective for T-type channels. Usually, vascular smooth 
muscles experience vasodilation, which decreases both blood pressure and peripheral resistance 
in the vascular vessels. Thus, chronic dosing of the drug often increases cardiac output slightly 
(DrugBank, 2016). Research has further demonstrated that Mibefradil slows the atrioventricular 
node and sinus conduction, which leads to an increase in peripheral resistance and decrease in 
the heart rate. In addition, the drug has been known to prolong the recovery time of the corrected 
sinus node and lengthen AH interval while raising the Wenckebach point (DrugBank, 2016). The 
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role of Mibefradil as a calcium channel blocker is essential to the antagonism of calcium 
channels that reverses the effects of FAS (member of the death receptor family). In our study 
with adipocytes, the calcium channel blocker Mibefradil had the unusual effect of raising 
intracellular calcium levels. It also induced lipid droplet fusion and cell death. Since calcium 
signaling has dual functions in the maintenance of homeostasis and the triggering of 
adipogenesis and lipid droplets regulate the storage and release of triacylglycerols, investigating 
the role of Mibefradil in calcium signaling, lipid droplet changes, and adipocyte apoptosis could 
provide us with possible strategies to control and overcome obesity. 
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3 RESULTS 
Application of Mibefradil to white adipocytes results in an increase in intracellular calcium. 
The first experiment was to test the effect of Mibefradil on intracellular calcium levels. White 
adipocytes were loaded with Fura-2 (see Methods for details).  We examined the effect of 
Mibefradil on these Fura-2 loaded adipocytes using a microscopy system specialized for fast 
calcium imaging (see Methods for details).  Baseline values were acquired for 5 minutes prior to 
the application of Mibefradil, and acquired 30 minutes after the addition of Mibefradil to a dish 
containing Fura-2 loaded adipocytes. Mibefradil application resulted in an increase in 
intracellular calcium, which was evident by the increase in the fluorescence intensity ratio 
following the Mibefradil treatment (Fig. 1A-E).  In most cases, after the maximum peak had 
been reached calcium levels declined close to baseline values seen prior to Mibefradil treatment 
(Fig. 1). Responses in individual adipocytes were variable though, as shown in Fig. 1D, where 
one cell upon 40 µM Mibefradil treatment responded with the characteristic rise and subsequent 
fall of calcium levels, while the other cell showed calcium levels that continued to rise after 
Mibefradil treatment.  
Analyzing experiments of white adipocytes treated with 10 µM Mibefradil showed a significant 
increase in calcium at P<0.001 (Fig 2). To determine dose-dependency of the drug, Mibefradil 
concentrations of 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM were each tested. Among the 
varying concentrations of Mibefradil on average an increase in intracellular calcium levels was 
seen about 3 min after addition (Fig. 1A-E). A 10 µM Mibefradil treatment resulted in an 
increase in intracellular calcium levels that reached an average maximum of 0.86± 0.09. 25 µM, 
30 µM, 40 µM, and 50 µM Mibefradil treatment resulted in increases in intracellular calcium 
levels that reached maximum values of 0.96 ± 0.06, 1.13 ± 0.19, 1.07 ± 0.06, and 1.25 ± 0.1, 
12 
respectively. Each of these concentrations induced a significant increase in calcium (P< 0.001). 
A One Way ANOVA test concluded that there was no overall significant difference (P>0.05) 
between treatments, suggesting that increasing concentrations of Mibefradil did not result in a 
dose-dependent effect (Fig. 3).  
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A.  
B.  
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C.  
D.  
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E.  
Figure 1 A-E. Representative examples of Mibefradil induced calcium increases in white 
adipocytes. Fluorescent intensity ratiometric graphs showing the response of different 
concentrations of Mibefradil. Arrow indicates time of Mibefradil application. Number of cells 
denoted by N. 
 
 
 
Figure 2. Mibefradil (10 µM) induced calcium increase in white adipocytes. Bar graph 
illustrates percent change of calcium. Mibefradil (MIB) dissolved in DMSO. DMSO treatment 
showed no significant increase in calcium levels (P>0.05). MIB treatment resulted in a 
significant increase in calcium peak levels (P<0.001). Number of cells denoted by N. 
 
16 
 
Figure 3. Different concentrations of Mibefradil induced calcium increases in white 
adipocytes. Bar graph illustrates average peak of calcium levels. Mibefradil dissolved in DMSO.  
There was no significant difference among the different concentrations of Mibefradil (ANOVA 
P>0.05). Number of cells denoted by N. 
 
Application of Mibefradil to white adipocytes in extracellular medium devoid of calcium. 
In order to test whether the increase in intracellular calcium upon treatment with Mibefradil was 
due to calcium influx into the cytoplasm, 10 µM Mibefradil was applied to adipocytes in an 
extracellular medium with nominally zero calcium and containing the calcium chelator EGTA 
(5mM). A 30 min treatment of white adipocytes with Mibefradil (10 µM) in a zero calcium 
medium led to a significant (P<0.001) increase in intracellular calcium. The lack of extracellular 
calcium did not interfere with Mibefradil’s effect of inducing a calcium increase in white 
adipocytes (compare to the effect of Mibefradil in normal medium, Figs. 1A, 2), suggesting that 
Mibefradil’s effect of raising the intracellular calcium concentration in adipocytes was not 
through calcium influx from the extracellular space, but likely resulted by calcium release from 
an intracellular source of calcium (Fig. 4). There was an apparent delay in the increase in 
0
25
50
75
100
125
150
175
200
225
250
A
v
e
ra
g
e
 p
e
a
k
 c
a
lc
iu
m
 c
o
n
c
e
n
tr
a
ti
o
n
 (
%
)
n=62 n=15 n=9 n=21 n=175n=282
10M MIB M MIB M MIB M MIB M MIBControl
Pre-MIB: 5min
17 
calcium levels, as well as a slower rise to peak in zero calcium medium, indicating that 
extracellular calcium might play an accessory role in producing a normal Mibefradil induced 
calcium response.   
 
A.  
B.  
Figure 4A-B. Mibefradil induced calcium increase in white adipocytes in a zero calcium 
environment. A) Representative graph of fluorescence excitation ratio (340nm/380nm) 
corresponding to intracellular calcium levels over a period of 30 min in white adipocytes treated 
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with 10 µM Mibefradil (MIB) in a zero calcium medium. B) Bar graph illustrates percent change 
of calcium levels. Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO peak showed no 
significant increase in calcium levels (P>0.05). Adipocytes treated with Mibefradil in a zero 
calcium environment showed a significant increase in calcium levels (P < 0.001). Number of 
cells denoted by N. 
 
Mibefradil does not cause a cytosolic calcium increase via release from the mitochondria 
Mitochondria are known calcium stores and we next examined the potential role of mitochondria 
in mediating the effect of Mibefradil on adipocytes. To deplete mitochondria of calcium, white 
adipocytes were pretreated with the oxidative phosphorylation uncoupler, FCCP. Addition of 
FCCP (10 µM) resulted in a transient increase in intracellular calcium levels that reached an 
average maximum value of 0.9 ± 0.05 and returned to pretreatment values within 30 min of 
application (Fig. 5). The increase in calcium levels following treatment was significantly 
different from controls (P<0.001). In order to test whether the effect of a rise in intracellular 
calcium levels by Mibefradil was attributed to release from the mitochondria, Mibefradil (40 
µM) was applied to adipocytes pretreated with FCCP.  
Experiments with white adipocytes pretreated with FCCP followed by a treatment with 
Mibefradil (40 µM) did not inhibit Mibefradil from inducing an increase in intracellular calcium 
levels (Fig. 6A). Interestingly, calcium levels continued to rise in pretreated cells and did not 
recover (Fig. 6A). This appeared to indicate that the uncoupling of mitochondria and the 
depletion of mitochondrial stores made cells increasingly susceptible to the Mibefradil induced 
calcium increase.   
Decreasing the concentration of Mibefradil to 30 µM produced similar results (Fig 7). 
Preincubation of 10 µM FCCP for 30 min did not block the effect of increasing intracellular 
calcium levels normally seen when Mibefradil was applied onto white adipocytes. When 
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comparing calcium levels before and after addition of Mibefradil in pretreated adipocytes with 
FCCP there was a significant difference at P<0.001 (Fig. 6B & 7B). Calcium levels after 
addition of Mibefradil did not return to pretreatment values and this result indicated that the 
source of calcium mobilized by Mibefradil was not the mitochondria. Given the strong and 
irreversible effect of 30µM Mibefradil on FCCP pre-treated adipocytes, future experiments 
should evaluate the effects of lower concentrations of Mibefradil.  
 
Figure 5. FCCP induced calcium increase in white adipocytes. A) Representative graph 
of fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels 
over a period of 30 min in white adipocytes treated with 10 µM FCCP. Number of cells denoted 
by N. 
 
 
20 
A.  
 
B.  
Figure 6A-B. Pretreatment of FCCP (10 µM) did not block Mibefradil (40 µM MIB) 
induced calcium increase in white adipocytes. A) Representative graph of fluorescence excitation 
ratio (340nm/380nm) corresponding to intracellular calcium levels over time in pretreated white 
adipocytes with 10 µM FCCP followed by 40 µM Mibefradil (MIB). B) Bar graph illustrates 
percent change of calcium levels. FCCP and Mibefradil dissolved in DMSO. DMSO (5 min) and 
DMSO (10min) showed no significant increase in calcium levels (P>0.05). Pre-FCCP (5 min) 
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and FCCP peak (10 min) showed a significant increase in calcium levels (P < 0.001). DMSO 
(35 min 30 sec) and DMSO (44 min) showed no significant increase in calcium levels (P>0.05).  
Post-FCCP (35min 30 sec) and Post-MIB peak (44 min) showed a significant increase in 
calcium levels (P < 0.001). The mitochondrial calcium store was depleted by treating cells for 
30 min with a mitochondrial oxidative phosphorylation uncoupler, 10 µM FCCP. Number of cell 
denoted by N. 
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A.  
B.  
Figure 7A-B. Pretreatment of FCCP (10 µM) did not block Mibefradil (30 µM MIB) 
induced calcium increase in white adipocytes. A) Representative graph of fluorescence excitation 
ratio (340nm/380nm) corresponding to intracellular calcium levels over time in pretreated white 
adipocytes with 10 µM FCCP followed by 30 µM Mibefradil (MIB). B) Bar graph illustrating 
percent change of calcium levels.  FCCP and Mibefradil dissolved in DMSO. DMSO (5 min) and 
DMSO (8 min) showed no significant increase in calcium levels (P>0.05). Pre-FCCP (5 min) 
and FCCP peak (8 min) showed a significant increase in calcium levels (P < 0.001). DMSO (35 
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min 30 sec) and DMSO (1hr 5 min) showed no significant increase in calcium levels (P>0.05).  
Post-FCCP (35 min 30 sec) and Post-MIB peak (1 hr 5 min) showed a significant increase in 
calcium levels (P < 0.001). The mitochondrial calcium store was depleted by treating cells for 
30 min with a mitochondrial oxidative phosphorylation uncoupler, 10 µM FCCP. Number of 
cells denoted by N. 
 
Mibefradil causes a cytosolic calcium increase via release from the endoplasmic reticulum 
To test whether the endoplasmic reticulum was involved in the mechanism mediating the effects 
of Mibefradil on calcium levels in white adipocytes, we employed an inhibitor of the calcium 
ATPase pump in the ER, Thapsigargin. Thapsigargin (10 µM) application by itself induced a 
calcium transient in adipocytes (Fig.8). Intracellular calcium levels reached a maximum of 
1.07 ± 0.06 following Thapsigargin application and returned to pretreatment values within 30 
minute of application. The increase in calcium levels following treatment was significant 
(P<0.001). We tested next the effects of application of Mibefradil to adipocytes pretreated with 
Thapsigargin. Following a 30 min treatment of Thapsigargin, Mibefradil was applied for a period 
of 30 min. Interestingly, the Mibefradil induced calcium increase was blocked in pretreated cells 
(Fig. 9). Preincubation of 10 µM Thapsigargin for 30 min blocked the effect of increasing 
intracellular calcium levels normally seen when Mibefradil was applied onto white adipocytes 
(P<0.001 compared with 10µM MIB alone; Fig 9c). Higher concentrations of Mibefradil (25 µM 
and 50 µM) were also tested (Figs. 10-11). At each of these concentrations, Thapsigargin 
abolished the Mibefradil induced calcium increase (Fig. 9-11). Taken together, these results 
suggested that Mibefradil induced calcium increase in white adipocytes was likely caused by 
calcium release from the endoplasmic reticulum.  
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Figure 8. Thapsigargin (THAP) induced a calcium increase in white adipocytes. A) 
Representative graph of fluorescence excitation ratio (340nm/380nm) corresponding to 
intracellular calcium levels over a period of 30 min in white adipocytes treated with 10 µM 
THAP. 
 
A.   
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B.  
C.  
Figure 9A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (10 µM 
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence 
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of 
30 min in white adipocytes treated with 10 µM Mibefradil (MIB). B) Representative graph of 
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over 
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 10 µM 
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels.  Thapsigargin and 
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Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (8 min) showed no significant 
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (8 min) showed a 
significant increase in calcium levels (P < 0.001). DMSO (36min) and DMSO (46 min) showed 
no significant increase in calcium levels (P >0.05). Post-THAP (36 min) and Post-MIB peak (46 
min) showed no significant increase in calcium levels (P>0.05). Intracellular Ca stores were 
depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10 µM THAP. Pretreatment 
with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001 when 
comparing pre-MIB calcium levels with Post MIB peak calcium levels.)  Number of cells denoted 
by N. 
 
A.  
B.  
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C.  
Figure 10A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (25 µM 
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence 
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of 
30 min in white adipocytes treated with 25 µM Mibefradil (MIB). B) Representative graph of 
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over 
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 25 µM 
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels.  Thapsigargin and 
Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (9 min) showed no significant 
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (9 min) showed a 
significant increase in calcium levels (P < 0.001). DMSO (35 min 30 sec) and DMSO (44 min 30 
sec) showed no significant difference (P>0.05). Post-THAP (35 min 30 sec) and Post-MIB peak 
(44 min 30 sec) showed no significant increase in calcium levels (P>0.05). Intracellular Ca 
stores were depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10ɥM THAP. 
Pretreatment with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001 
when comparing pre-MIB calcium levels with Post MIB peak calcium levels.) Number of cells 
denoted by N. 
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A.  
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C.  
Figure 11A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (50 µM 
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence 
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of 
30 min in white adipocytes treated with 50 µM Mibefradil (MIB). B) Representative graph of 
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over 
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 50ɥM 
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels.  Thapsigargin and 
Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (8 min 30 sec) showed no significant 
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (8 min 30 sec) showed a 
significant increase in calcium levels (P < 0.001). DMSO (17 min) and DMSO (34 min 30 sec) 
showed no significant increase in calcium levels (P>0.05). Post-THAP (17 min) and Post-MIB 
peak (34min 30 sec) showed no significant increase in calcium levels (P>0.05). Intracellular Ca 
stores were depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10ɥM THAP. 
Pretreatment with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001 
when comparing pre-MIB calcium levels with Post MIB peak calcium levels.). Number of cells 
denoted by N. 
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Application of Mibefradil to white adipocytes results in lipid droplet fusion. 
Our first experiment of treating adipocytes with Mibefradil did not only result in increased 
intracellular calcium levels, but also induced smaller lipid droplets within cells to fuse to form 
larger droplets. Lipid droplet fusion was evident by comparing differential interference contrast 
(DIC) images of adipocytes before and after treatment (Fig. 12 A). Also, shown are images of 
Fura-2 loaded adipocytes (380nm excitation) before and after lipid droplet fusion (Fig. 12B). To 
investigate any dose-dependent effect of Mibefradil on lipid droplet fusion, the following 
concentrations were used: 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM.  Each of these Mibefradil 
concentrations induced fusion (Tables 2a-6a). 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM 
Mibefradil treatment resulted in lipid droplet fusion percentage values of 7.2 ± 2.9% (4 
experiments), 34.5% (1 experiment), 45.5% (1 experiment), 16.4±8.1% (2 experiments), and 
39.4±4.8% (9 experiments), respectively. Both 10 µM and 50 µM Mibefradil concentrations 
based on average values showed dose dependency whereby increasing concentrations produced 
an increased amount of lipid droplet fusion. Intermediate concentrations (25 µM, 30 µM, 40 µM) 
did not based on average values did show dose dependency, which could be due to the low 
number experiments performed with these concentrations. Only one experiment was completed 
for each of the 25 µM and 30 µM Mibefradil treatment and two experiments were completed for 
the 40 µM Mibefradil treatment. Therefore, dose dependency for these intermediate 
concentrations cannot be determined and additional experiments utilizing these Mibefradil 
concentrations need to be performed. 
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A.  
B.  
Figure 12A-B. A) Differential interference contrast image of unstained white adipocytes 
before (left) and after treatment with Mibefradil (right). Mibefradil (25 µM) treatment induced 
lipid droplets to fuse (above). B) Ratiometric image of fura-2 loaded white adipocytes before 
(left) and after treatment with Mibefradil (right). Mibefradil (25 µM MIB) treatment induced 
lipid droplets to fuse. Some fusion events are shown by arrows. Regions of interest (ROI) 
indicate areas of the cells used to measure Fura-2 fluorescence. White bar: 10 µm. 
  
Application of Mibefradil to white adipocytes in an extracellular medium devoid of calcium 
induced lipid droplet fusion. 
Lipid droplet fusion was a common occurrence after treating white adipocytes with Mibefradil. 
We investigated next whether the Mibefradil induced lipid droplet fusion depended on the 
presence of extracellular calcium. When adipocytes were treated with Mibefradil in a zero-
calcium environment lipid droplet fusion was present in adipocytes (Table 1). In a medium 
containing calcium, Mibefradil (40µM) treatment resulted in 16.4±8.1% of cells (n= 2 
experiments) showing lipid droplet fusion, while 49.4±12.0% of cells (n=3 experiments) showed 
fusion with the same treatment in a medium without calcium.  These results suggested that 
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Mibefradil induced lipid droplet fusion was not inhibited by the lack of extracellular calcium. 
Fusion events in zero calcium were actually numerically higher, but given the low number of 
experiments and variability in results, additional experiments would have to be performed to test 
whether this trend was significant.  
Table 1. Lipid droplet fusion in white adipocytes treated with 40 µM Mibefradil in 
normal and in zero calcium containing extracellular medium. Note that lipid droplet fusion 
ranged widely between experiments. Number cells denoted by N. 
 
 
Application of Mibefradil to white adipocytes pretreated with FCCP induced lipid droplet fusion. 
Previous experiments had demonstrated that Mibefradil treatment of adipocytes pretreated with 
an oxidative phosphorylation uncoupler, FCCP, still resulted in an increase in intracellular 
calcium levels attributed to Mibefradil. To test whether FCCP pretreatment had an effect on 
Mibefradil induced lipid droplet fusion, cells were pretreated with FCCP (10µM) for 30min. 30 
min treatment with FCCP (10 µM) alone induced 0% lipid droplet fusion (2 experiments).  The 
application of Mibefradil to FCCP pretreated adipocytes induced lipid droplet fusion (Table 2). 
A 40 µM Mibefradil application to FCCP pretreated cells induced fusion in 10.7±6.4% of cells 
(n=2 experiments), compared to 16.4±8.1% in 40µM Mibefradil alone (n=2 experiments). At 30 
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µM, Mibefradil application induced fusion in 39.1±29.3% of FCCP pretreated cells (n=2 
experiments), compared to 45.5% of cells for Mibefradil alone (n=1 experiment). Clearly, FCCP 
pretreatment of adipocytes did not inhibit Mibefradil induced lipid droplet fusion, but due to the 
low numbers of experiments and variability in results between experiments, no statistical 
analysis was warranted. A 40 µM Mibefradil treatment in pretreated adipocytes did not show a 
significant difference (P<0.001) in lipid droplet fusion when compared to a Mibefradil (30 µM) 
treatment alone. It would be important to increase the number of experiments in future studies to 
test possible dose dependency of the effect of Mibefradil and any effect of FCCP pretreatment on 
lipid droplet fusion. 
Table 2. Lipid droplet fusion in white adipocytes pretreated with FCCP followed by 
different Mibefradil concentrations. R1: 30 µM Mibefradil, R2: 40 µM Mibefradil. Note that 
lipid droplet fusion ranged widely between experiments. Number of cells denoted by N.  
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Application of Mibefradil to white adipocytes pretreated with Thapsigargin prevented lipid 
droplet fusion. 
As shown above, pretreatment of adipocytes with Thapsigargin inhibited Mibefradil induced 
calcium increase. Next, we investigated whether Thapsigargin pretreatment would, in addition to 
its effect on abolishing Mibefradil induced calcium increase, also have an effect on lipid droplet 
fusion attributed to Mibefradil.  White adipocytes treated only with Thapsigargin (10 µM) did 
not show any lipid droplet fusion. Pretreatment with Thapsigargin followed by the application of 
10µM and 25µM Mibefradil fully blocked the Mibefradil induced effects of fusion (Table 3), 
whereas fusion was observed in 3 out of 7 experiments at 50µM Mibefradil, suggesting that 
higher doses of Mibefradil might have overcome the effect of emptying the ER stores of calcium. 
Thus, in most cases, fusion was inhibited when endoplasmic reticulum (ER) calcium stores were 
emptied by Thapsigargin, suggesting that calcium release from the ER is an important factor in 
causing Mibefradil induced lipid droplet fusion.  
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Table 3. Lipid droplet fusion in white adipocytes pretreated with Thapsigargin followed 
by different Mibefradil concentrations. R1: 10 µM Mibefradil, R2: 25 µM Mibefradil, R3: 50 µM 
Mibefradil. Note that lipid droplet fusion ranges widely between experiments. Number of cells 
denoted by N. 
 
Calcium levels in white adipocytes undergoing lipid droplet fusion induced by Mibefradil vary 
considerably. 
The finding that Thapsigargin inhibited both Mibefradil induced calcium increase and lipid 
droplet fusion suggested a possible link between calcium and lipid droplet fusion. To further 
investigate the relationship between the intracellular calcium concentration and lipid droplet 
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fusion, we analyzed the fusion events and correlated them to the calcium levels. Fusion of lipid 
droplets was associated with a wide range of calcium levels (Fig.13). A more detailed analysis of 
correlating the intracellular calcium concentration of the adipocyte as lipid droplets fused is 
shown in Figure 14. Fig. 14A, shows adipocytes that fused after the concentration of calcium had 
been reduced from its initial peak. In fig. 14B, fusion also did not coincide with the initial 
calcium peak, but occurred at a later time point at which the calcium concentration was still 
elevated close to the level of the initial calcium peak. Fig. 14C shows examples of cells in which 
the calcium concentration continued to increase and fusion occurred at a time when the 
concentration of calcium was higher than the calcium concentration of the 1st peak.  Taken 
together, adipocytes underwent lipid droplet fusion at varying intracellular calcium 
concentrations. Additionally, lipid droplet fusion occurred at varying times after the first calcium 
peak had been reached, suggesting that the initial rise in calcium may have triggered signaling 
events that resulted in lipid fusion further downstream. The majority of lipid droplet fusion 
events in white adipocytes treated with Mibefradil took place between 13-19 min (Fig. 15). Thus, 
lipid droplet fusion occurred 8-14 min after Mibefradil addition. 
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Figure 13. Calcium levels corresponding to lipid droplet fusion in white adipocytes 
treated with 50 µM Mibefradil. This plot illustrates lipid droplet fusion occurred at varying 
levels of calcium, ranging from ratios as high as 2.6 to as low as 0.5. Each dot represents a 
single cell. 
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B.  
C.  
Figure 14. Calcium levels of white adipocytes treated with 50 µM Mibefradil (MIB) at 
three major stages: Pre-Mibefradil levels, 1st peak (Post-Mibefradil), and Fusion.  A-C) Graphs 
show fusion of lipid droplets within adipocytes occurred at varying calcium levels. Pre-
Mibefradil represent calcium concentration of adipocytes prior to Mibefradil treatment. The 
maximum calcium levels post Mibefradil treatment is represented as 1st peak. The calcium levels 
at which lipid droplets fused within adipocytes is represented by fusion. Number of cells denoted 
by N. 
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Figure 15. Calcium levels at time of lipid droplet fusion in white adipocytes treated with 
50 µM Mibefradil. Scatter plot showing lipid droplet fusion frequently occurring between 13-19 
min post treatment.  
 
Mibefradil induced lipid droplet fusion preceded cell death in white adipocytes. 
Previous experiments demonstrated that Mibefradil, in addition to causing an increase in 
intracellular calcium levels and subsequent lipid droplet fusion, also resulted in the death of 
some white adipocytes at various times throughout the 30-minute treatment period. Death was 
accompanied by the disintegration of the plasma membrane of white adipocytes and the release 
of the cells’ contents into the extracellular medium (Fig. 16). The effect of the different 
concentrations of Mibefradil on cell death appeared to show dose dependency between 10 µM 
and 50 µM, whereby increasing concentrations produced an increased amount of cell death 
(Table 6). A 10 µM Mibefradil treatment induced on average 1.6±1.0% cell death in white 
adipocytes (n=4 experiments) (Table 6). A 50 µM Mibefradil treatment induced on average 
36.8±9.7% cell death (n=9 experiments). Intermediate concentrations (25 µM, 30 µM, 40 µM) 
based on average values did not show dose dependency. A 25 µM Mibefradil treatment induced 
on average 3.4% cell death (n= 1 experiment) (Table 6). A 30 µM Mibefradil treatment induced 
on average 30.3% cell death (n=1 experiment) (Table 5). A 40 µM Mibefradil treatment induced 
on average 29.9±25.7% cell death in adipocytes (2 experiment) (Table 4). However, the low 
40 
number of experiments could be the reason for the wide range in cell deaths seen at the 
intermediate concentrations. Only one experiment was completed for each of the 25 µM and 30 
µM Mibefradil treatment and two experiments were completed for the 40 µM Mibefradil 
treatment. While cell death was clearly higher at 50µM compared to 10µM of Mibefradil, 
additional experiments utilizing intermediate Mibefradil concentrations needed to be performed 
to establish a statistically significant dose dependency for the effect of Mibefradil on cell death. 
Taken together, these experiments suggested that Mibefradil had a detrimental effect on the long-
term viability of adipocytes. Next, we investigated whether the source of the Mibefradil induced 
calcium increase would have an effect on Mibefradil induced cell death. Mibefradil induced cell 
death was still present in adipocytes either deprived of extracellular calcium (Table 4) or 
depleted of calcium from the mitochondrial store (Table 5). However, cell death was nearly 
abolished in adipocytes deprived of intracellular calcium from the endoplasmic reticulum (Table 
6).  Adipocytes pretreated with Thapsigargin followed by a 10 µM Mibefradil treatment showed 
0% cell death. Zero percent cell death was also seen in 25 µM Mibefradil treatment in pretreated 
cells. Only 0.3±0.3% cell death was seen in pretreated adipocytes following a 50 µM Mibefradil 
treatment. These results suggested that Mibefradil induced cell death could be nearly completely 
blocked when the endoplasmic reticulum calcium store had been previously emptied by 
Thapsigargin. The important role of the endoplasmic reticulum in enabling Mibefradil to induce 
cell death merits further research to better understand the mode of Mibefradil’s action in white 
adipocytes. 
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Figure 16. Differential interference contrast image of unstained white adipocytes treated 
with Mibefradil. Mibefradil (25 µM) treatment induced cell death in white adipocytes. Right 
image shows cell membrane disintegration and diffusion of cell contents into the extracellular 
medium.  White arrow shows intact plasma membrane before (left) and after disintegration of 
adipocytes treated with Mibefradil (right). 
 
Table 4. Cell death in white adipocytes treated with 40 µM Mibefradil concentrations in 
zero calcium and normal calcium containing extracellular medium. Note that cell death ranges 
widely between experiments. Number of cells denoted by N. 
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Table 5. Cell death in white adipocytes pretreated with FCCP followed by different 
Mibefradil concentrations. R1: 30 µM Mibefradil, R2: 40 µM Mibefradil. Note that cell death 
ranges widely between experiments. Number of cells denoted by N. 
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Table 6. Cell death in white adipocytes pretreated with Thapsigargin followed by 
different Mibefradil concentrations. R1: 10 µM Mibefradil, R2: 25 µM Mibefradil, R3: 50 µM 
Mibefradil. Note that cell death ranges widely between experiments. Number of cells denoted by 
N. 
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4 CONCLUSIONS 
The role of white adipose tissue in our bodies is of central interest to many researchers interested 
in combating the epidemic of obesity among developed nations around the world. White adipose 
tissue (WAT) is mainly located in subcutaneous regions of the abdomen and wraps around internal 
organs often referred to as visceral fat. White adipose tissue functions as the storage site for fat 
and in obese individuals there is an excessive amount of dietary fat (Bjorndal 2011). Normally in 
WAT, fat in the form of triglycerides is broken down into fuel, or free fatty acids, for instances 
when energy expenditure exceeds food intake. However, in obese individuals, there is an 
abundance of free fatty acids in the blood being released by an abnormally enlarged adipose tissue 
mass (Boden 2008). The excess of triglycerides, composed of free fatty acids, is stored in lipid 
droplets. The study of lipid droplets in the scientific community now known as lipid droplet 
biology has, through genetic techniques, focused primarily on the various proteins located on the 
membrane of lipid droplets (Konige 2014). Lipid droplets are dynamic organelles that function to 
store energy mainly in the form of triacylglycerol. The mobilization of these lipids is dependent 
on whether the mammal is under fed or fasting conditions. Fed conditions typically accompany an 
excess of calories which promote the generation and storage of triacylglycerols into the large, 
unilocular lipid droplets found within white adipocytes. While at a time of fasting conditions 
associated with caloric deficit the mobilization of fatty acids via regulated lipolysis of stored 
triacylglycerols ensues (Brasaemle 2009; Paar 2012).  
Mibefradil is a calcium channel antagonist that binds to transient low voltage activated T-type 
calcium channels mainly located in vascular smooth muscle, neurosecretory cells in the brain, 
kidneys, adrenal gland and pacemaker cells (Ernst and Kelly 1998). Once bound Mibefradil blocks 
the influx of extracellular calcium through T-type channels and has numerous effects on these 
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different tissues. Some recent studies have shown that Mibefradil is potentially capable of 
preventing cancer cell proliferation and induce tumor suppression activity (Huang, Lu et al. 2015, 
Gomez-Lagunas, Carrillo et al. 2016). An interesting phenomenon occurred in the process of using 
Mibefradil in preliminary experiments on white adipocytes meriting future investigation. 
Mibefradil induced an increase in intracellular calcium levels, unexpected for a T-type calcium 
channel blocker. Additionally, it also induced lipid droplet fusion in white adipocytes.    
 
Intracellular calcium increase in murine white adipocytes due to Mibefradil 
Calcium participates in a variety of complex cellular processes, as it is a vital intracellular 
secondary messenger. A critical function of this messenger is to produce calcium signals (Berridge 
1997). This messenger depends on intracellular calcium stores and influx to produce these signals. 
Consequently, we predicted that the mechanism by which Mibefradil caused a rise in intracellular 
calcium was due either to calcium influx or calcium release from internal stores. Accordingly, the 
present experiments tested whether an external medium deficient in calcium would attenuate 
Mibefradil induced calcium increase. Subsequently we tested whether Thapsigargin-induced 
depletion of intracellular endoplasmic reticulum calcium store as well as FCCP-induced depletion 
of the mitochondrial store would prevent Mibefradil induced calcium increase. 
Our first experiment aimed at confirming that Mibefradil increased cytoplasmic calcium within 
white adipocytes. Mibefradil application (10-50 µM) repeatedly increased the intracellular calcium 
concentration in Fura-2-loaded 3L1L cells. The next question was to determine whether 
Mibefradil’s mechanism to induce calcium increase was due to calcium influx. Cells were tested 
in a calcium-free medium and treated with Mibefradil. Mibefradil produced an increase in 
cytosolic calcium on white adipocytes of the same magnitude than Mibefradil in regular 
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extracellular medium that contained normal levels of calcium. The finding that Mibefradil still 
induced an increase in calcium levels under conditions of calcium depleted extracellular 
environment suggested that intracellular stores likely served as the main source of calcium.  
We next investigated the source of Mibefradil induced calcium increase in cells treated with 10µM 
FCCP to deplete mitochondria calcium stores. The effects of the pretreatment of white adipocytes 
with FCCP did not prevent the Mibefradil induced calcium increase. Mibefradil still caused a rise 
in calcium levels in white adipocytes that had been pretreated with the mitochondrial uncoupler 
FCCP, indicating that this organelle is unlikely the source of the Mibefradil induced increase in 
calcium in white adipocytes. 
We next investigated the role of endoplasmic reticulum stores of calcium as the source of the 
Mibefradil induced calcium increase. Thapsigargin irreversibly blocks the endoplasmic reticulum 
Ca-ATPase pump and thereby prevents the refilling of the ER stores, resulting in calcium store 
depletion. Thapsigargin (10µM) application to white adipocytes resulted in a transient increase in 
intracellular calcium levels. Depletion of Thapsigargin-sensitive calcium stores did prevent the 
Mibefradil induced calcium increase in white adipocytes, suggesting that the calcium source 
mobilized by Mibefradil was the endoplasmic reticulum. Therefore, we propose that the direct 
source of calcium after Mibefradil treatment in mouse white adipocytes is through endoplasmic 
reticulum channels. Identifying the mechanism in which the blocking of T-type calcium channels 
by Mibefradil resulted in calcium release from the endoplasmic reticulum requires further research. 
Alternatively, Mibefradil might have acted by a mechanism other than the known inhibition of T-
type calcium channels. 
 
Lipid droplet fusion in murine white adipocytes due to Mibefradil 
47 
Adipose tissue is highly specialized to be the main lipid storage tissue in the body. These cells are 
responsible for the management and packaging of lipid stores. Unilocular lipid droplets present in 
white adipocytes are well adapted to store large amounts of lipids, and the size of its lipid droplet 
takes up a large portion of the cytoplasm. The increasing size of lipid droplets is frequently seen 
because of overnutrition in obese individuals. These dynamic organelles are devoted to providing 
the most efficient recycling and storing of excessive and gross amounts of fatty acids. Disruptions 
in these processes lead to the disabling of lipid droplets to protect against lipotoxicity (Krahmer 
2013; Walther 2012). In white adipocytes, the chief event in the progression of obesity is the 
evolution of lipid droplets transforming from a small lipid droplet to a large lipid droplet (WU 
2014).  In our study, time lapse fluorescence microscopy showed that Mibefradil treatment also 
induced lipid droplet fusion in white adipocytes.  Live cell imaging of murine adipocytes revealed 
that pretreatment with the endoplasmic reticulum CaATPase pump inhibitor, Thapsigargin, 
prevented lipid droplet fusion in addition to blocking Mibefradil induced calcium increase. These 
data indicate that the release of calcium from intracellular stores is required for lipid droplet fusion 
because in the presence of Thapsigargin both fusion events and calcium increase induced by 
Mibefradil were blocked. To test whether the release of calcium from stores is sufficient for lipid 
droplet fusion, other experiments such as the release of calcium from intracellular stores using 
caged IP3 should be performed.  
 
Cell death in murine white adipocytes due to Mibefradil 
Many proteins are located on the surface of lipid droplets. These proteins are devoted towards 
regulating the synthesis of lipids, enacting fusion of lipid droplets and mediating the hydrolysis of 
lipids. Lipid droplet fusion has been directly linked to FSP27/CIDEC proteins. It has been 
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demonstrated that the overexpression of these proteins generates larger and fewer lipid droplets 
via homotypic fusion (Urritia 2015). The deviation of a controlled amount of triacylglycerol in 
storage is regulated by specialized proteins on lipid droplets. However, inhibition of these 
adipocyte-specific lipid droplet-associated proteins can induce lipotoxicity. An essential role of 
lipid droplets is to quarantine overaccumulated lipids from entering the cytosol of adipocytes and 
thereby safeguarding the adipocyte from the damaging effect of amassing excessive free fatty acids 
(FFA). An elevated release of FFA from enlarged adipocytes initiates inflammation and lipolysis 
in adipose tissue (Matsuda 2013). In our study, Mibefradil caused the lipid droplets to fuse into 
large unilocular lipid droplets and subsequently caused the disintegration of the plasma membrane 
of the adipocyte. Mibefradil induced adipocyte apoptosis and while its mode of action is presently 
unclear, it is possible that the drug could be targeting surface proteins on lipid droplets and interfere 
with their purpose of managing and providing the most efficient packaging of lipids. 
 
Mibefradil as a prospective drug treatment 
The work on Mibefradil’s effects on adipocytes is noteworthy because currently Mibefradil is in 
the spotlight in the disciplines of cancer research and drug development. It has been found that T-
type calcium channels are highly expressed in numerous cancer cells. This includes a wide range 
of cells such as ovarian, glioma, breast, leukemic, and many others (Huang 2015). The drug 
Mibefradil is highly specific for T-type calcium channels and is a “potent” inhibitor of these 
channels, making Mibefradil a very promising therapeutic for fighting cancer (Huang 2015). 
Recently the National Cancer Institute (NCI) Adult Brain Tumor Consortium has placed 
Mibefradil in a phase 1b clinical trial as an anticancer agent that can be used for tumor treatment. 
The drug company Tau Therapeutics LLC has been developing Mibefradil to be a suitable drug 
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for the treatment of cancer. They are introducing Mibefradil as a sequential combination treatment 
with other antitumor applications to provide the maximal efficiency of targeted cancer treatment 
(Krouse 2015). The unexpected effects of Mibefradil in white adipocytes described in this study 
need to be considered as Mibefradil is advanced as a drug in human subjects. Changes in calcium 
dynamics, such as increases in calcium levels resulting in lipid droplet fusion in response to 
Mibefradil in white adipocytes require attention as they could signal previously unreported side 
effects of the drug.  
Adipocyte function can be altered by abnormal deviations in calcium levels. There is mounting 
evidence that dysfunction of calcium homeostasis in adipose tissue is coupled to metabolic 
diseases. It was reported that isolated adipocytes from obese individuals in the senescent 
population have increased levels of cytosolic calcium (Byyny 1992). Elevated cytosolic calcium 
levels are implicated to be a part of obesity-related diseases due to the calcium deposits 
surrounding lipid droplets within hypertrophic adipocytes (Giordano 2013). In addition, it has been 
found that an escalation of cytosolic calcium led to the modulation of de novo lipogenesis via 
regulation of FAS expression and in turn stimulates triglyceride build-up and expands lipid 
storage. FAS is part of the death- inducing signaling complex and functions to signal apoptosis 
(Zemel 2000). In this study, Mibefradil’s effect of accumulating excess calcium in the cytoplasm 
of white adipocytes led to compromised cells and cell death. Coupled with Mibefradil emerging 
as a potential therapeutic application for the treatment of cancer, this drug can also be designed to 
target hypertrophic adipocytes.  Today medicines in design and development are focused on 
having multi-purpose pharmacological and interventional approaches that treat more than a single 
underlying disease. One such development the compound 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), an active metabolite of vitamin D, which is being used as a preventive and 
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therapeutic agent against both breast cancer and obesity. 1,25-dihydroxyvitamin D3 also acts as a 
hormone that activates an apoptotic calcium signal that induces an increase in intracellular calcium 
levels in breast cancer cells and adipocytes causing apoptosis. The study of this compound has not 
only shed light on the link between obesity and breast cancer, but also discovered that the 
modulation of apoptosis is a viable and effective means to attenuate the pathways in obesity and 
breast cancer (Sergeey 2013). 
In the world of obesity research, understanding the way Mibefradil exerts effects such as calcium 
release, lipid droplet fusion, and cell death on adipocytes is crucial in unearthing its potential as a 
therapeutic. Manmade drugs that in addition to their known function also indirectly activate other 
unknown processes within a cell are an opportunity for scientists to design novel drugs that exploit 
the cells and their natural functions in our bodies for other purposes. Mibefradil changes adipocytes 
in interesting ways and further research into engineering pharmacological changes and repurposing 
its function in adipocytes should be pursued. 
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